Business Context and Reporting Period
This Form 8-K filing by NantKwest, Inc. (not Immunitybio, Inc.) covers events occurring on September 18, 2017. The registrant is a Delaware corporation headquartered in San Diego, California, and is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Resignation: Richard Kusserow resigned from the Board of Directors effective September 18, 2017. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Frederick W. Driscoll was appointed to the Board effective September 18, 2017, with a term expiring at the 2018 annual meeting. He will serve on the Audit Committee.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the background of the new director and the terms of his appointment. No financial guidance or outlook is provided in this filing.
Director Compensation for Frederick W. Driscoll
- Initial Equity Grant: Restricted Stock Units (RSUs) valued at $325,000, vesting monthly over three years, subject to continued service.
- Annual Equity Grant: Eligible for annual RSU grants valued at $100,000, vesting one year from the grant date.
- Cash Compensation:
- $50,000 annually for Board service.
- $10,000 annually for Audit Committee membership.
- $10,000 annually for serving as Audit Committee Chairman.
- Expenses: Reimbursement for all reasonable expenses.
Investor Verification Checklist
- Verify the correct registrant name is NantKwest, Inc., as the input metadata referenced Immunitybio, Inc.
- Confirm the independence status of the Board following the resignation of Richard Kusserow.
- Review the vesting schedule and forfeiture conditions of the $325,000 RSU grant to Frederick W. Driscoll.
- Check subsequent filings for the impact of the new Audit Committee leadership on financial reporting oversight.